Tesamorelin and Liver Fat: What Studies in People With HIV Show

Keep research and indication apart

EGRIFTA is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Labeling does not add a fatty-liver, NAFLD, or MASLD indication.⁴

There are, still, randomized trials that measured liver fat in people with HIV. That is clinical research. It is not the approved indication. This page keeps those facts in separate columns and does not generalize to people without HIV.

It is also not a treatment guide. The visceral-fat pivotal context is in the visceral-fat trials and in the tesamorelin hub.

The 2014 randomized trial

Stanley and colleagues published in JAMA: “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.” The population was 50 people with HIV and abdominal fat accumulation. The design was a randomized clinical trial.¹

The study investigated visceral fat and liver fat. It is a smaller trial than the 412- and 404-participant pivotals. It adds a liver question that the approval pivotals did not carry as an indication. It does not, by its size or its endpoint, make tesamorelin an approved liver drug.^1,5,6

The 2019 Lancet HIV trial

Stanley and colleagues published in The Lancet HIV: “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.” Sixty-one people were enrolled. The primary endpoint was hepatic fat fraction.²

That trial provides randomized human evidence on liver fat in people with HIV. The original title uses NAFLD. That word is kept here. The historical title is not rewritten to modernize it.

NAFLD and MASLD

NAFLD — non-alcoholic fatty liver disease — is the term the original publications used. MASLD — metabolic dysfunction-associated steatotic liver disease — is a later label for the same family of disease. Explaining the modern label does not authorize erasing the historical term from the titles.

Using MASLD in a context sentence does not turn the 2019 trial into an “approved MASLD” trial. It remains clinical research in people with HIV, under the name the authors chose.

What endpoints changed

Both trials measured fat compartments by imaging or spectroscopy, not a liver-approval record. The 2014 trial combined visceral fat and liver fat. The 2019 trial set hepatic fat fraction as the primary endpoint.^1,2

Those imaging changes are trial results. They are cited to describe what was studied. They are not cited to indicate a fatty-liver treatment, for people with HIV or for anyone else.

What remains uncertain

• EGRIFTA does not have an FDA indication for NAFLD, MASLD, or another liver use.⁴
• The sample sizes — 50 and 61 enrolled — are smaller than the visceral-fat pivotals.
• The results are not generalized to people without HIV.
• A 2024 analysis of participants from an existing trial, in an integrase-inhibitor context, is a subgroup or secondary analysis. It is not a new independent randomized trial.³
• None of this liver literature approves Peptra research material or makes it equivalent to EGRIFTA.

Current approved indication

The current indication remains reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Labeling adds that the product is not indicated for weight-loss management and that long-term cardiovascular safety has not been established.⁴

Clinical research ≠ FDA-approved liver indication. That sentence is the frame of this page. For regulatory status, not the liver trial, read EGRIFTA, FDA & WADA.

A tesamorelin COA is also not read here as liver-effect evidence. A certificate describes a research lot. It does not measure hepatic fat fraction, does not enroll participants, and does not extend the EGRIFTA indication. The population of these trials — people with HIV and abdominal fat accumulation — remains at the center of what can be stated.

If the question is body weight rather than liver, the visceral-fat-versus-weight page reminds readers that labeling does not indicate EGRIFTA for weight-loss management. If the question is identity, the definition page separates the 44-amino-acid analogue, the licensed product, and the research material.